Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros

Banco de datos
Tipo del documento
Revista
País de afiliación
Intervalo de año de publicación
1.
Retina ; 30(3): 468-72, 2010 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-19952991

RESUMEN

PURPOSE: The purpose was to study the histology of the fibrovascular membranes in proliferative diabetic retinopathy (PDR) with an intravitreal injection of bevacizumab. METHODS: Light and electron microscopic studies were performed on surgical specimens obtained during a pars plana vitrectomy from 6 PDR eyes after intravitreal injection of bevacizumab. The patients had preoperatively received no or scant retinal photocoagulations. The presence and distribution of CD34 was assessed as a marker of vascular endothelium using immunostaining. The presence of vascular endothelial growth factor was stained with a method of immunostaining. As controls, we examined 7 surgical specimens from 7 PDR eyes obtained during pars plana vitrectomy without bevacizumab therapy. All control patients had preoperatively received full or nearly full pan retinal photocoagulations. RESULTS: Light microscopy showed that the CD34-positive vascular endothelial cells formed capillarylike structures in the fibrovascular membranes of all 13 PDR eyes. Vascular endothelial growth factor was positively stained in the vascular endothelium of both groups; however, the number of vascular endothelial growth factor-positive vascular endothelial cells significantly decreased in the fibrovascular membranes with intravitreal injection of bevacizumab. Electron microscopy showed the newly formed vascular endothelial cells with junctional complex in both groups. CONCLUSION: The vascular endothelial cells with decreased expression of vascular endothelial growth factor are still present in the fibrovascular membranes of patients with PDR after intravitreal injection of bevacizumab.


Asunto(s)
Inhibidores de la Angiogénesis/administración & dosificación , Anticuerpos Monoclonales/administración & dosificación , Retinopatía Diabética/diagnóstico , Retinopatía Diabética/tratamiento farmacológico , Endotelio Vascular/patología , Vasos Retinianos/patología , Adulto , Anciano , Anticuerpos Monoclonales Humanizados , Antígenos CD34/metabolismo , Bevacizumab , Capilares , Retinopatía Diabética/cirugía , Endotelio Vascular/metabolismo , Femenino , Fibrosis , Humanos , Inyecciones , Masculino , Persona de Mediana Edad , Vasos Retinianos/metabolismo , Factor A de Crecimiento Endotelial Vascular/antagonistas & inhibidores , Factor A de Crecimiento Endotelial Vascular/metabolismo , Vitrectomía , Cuerpo Vítreo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA